GSK says personalized medicine is not ready for prime time

We spoke with Dongzhou Liu, Assistant Director of New Products R&D at GlaxoSmithKline (GSK), about open innovation and personalized medicine at the Executive Summit on Licensing and Innovation at the 2009 Molecular Medicine Tri-Conference in San Francisco.  In contrast to Roche Diagnostics' enthusia...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Biogen's Alzheimer's disease drug approval triggers controversy but also hints at new business opportunities

Analyst Insight | June 08, 2021

Biogen's recent FDA approval for an Alzheimer's disease (AD) drug is arguably the biggest news this week in the healthcare industry. Both Biogen's and its development partner Eisai's stock prices jumped more than 50% on the announcement. Yet, many dementia experts were quick to point out that the ... Not part of subscription

Therapeutic efficacy using gene therapy for Huntington's disease can be tracked using digital biomarker

News Commentary | July 08, 2021

Huntington's disease (HD) is a slow and fatal neurodegenerative disease with no cure in sight. HD is caused by a mutation in the Huntingtin gene. This also makes it the perfect candidate to address with gene therapy. However, an unsolved challenge was how to measure therapeutic efficacy before the ... Not part of subscription

NHS launches world's largest liquid biopsy trial, which could potentially detect 50 types of cancer

News Commentary | September 17, 2021

NHS will use GRAIL's Galleri test in this study, which aims to recruit 140,000 volunteers in eight areas of England. Besides being touted as the world's first and largest clinical trial of its kind, the more important significance of this study is that it is being spearheaded by one of the largest ... Not part of subscription